Literature DB >> 10146975

The cost of migraine: more than just a headache?

P J Davey, S R Leeder.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 10146975     DOI： 10.2165/00019053-199202010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  7 in total

1.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

2.  Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. (Health Policy, 8(1987) 317-323).

Authors:  T A Hodgson
Journal:  Health Policy       Date:  1989       Impact factor: 2.980

3.  Healthcare resource and lost labour costs of migraine headache in the US.

Authors:  J T Osterhaus; D L Gutterman; J R Plachetka
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

4.  Economic analysis and clinical trials.

Authors:  M F Drummond; G L Stoddart
Journal:  Control Clin Trials       Date:  1984-06

5.  Estimating the direct costs of illness.

Authors:  A A Scitovsky
Journal:  Milbank Mem Fund Q Health Soc       Date:  1982

6.  The economic costs of non-insulin-dependent diabetes mellitus.

Authors:  D M Huse; G Oster; A R Killen; M J Lacey; G A Colditz
Journal:  JAMA       Date:  1989-11-17       Impact factor: 56.272

7.  Treatment of acute migraine with subcutaneous sumatriptan.

Authors:  R K Cady; J K Wendt; J R Kirchner; J D Sargent; J F Rothrock; H Skaggs
Journal:  JAMA       Date:  1991-06-05       Impact factor: 56.272
  7 in total
  11 in total

1.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

2.  Resource allocation within Australian indigenous communities: a program for implementing vertical equity.

Authors:  V Wiseman; S Jan
Journal:  Health Care Anal       Date:  2000

Review 3.  The economic cost of epilepsy: a review.

Authors:  M Brunetti; E Pagano; L Garattini
Journal:  Ital J Neurol Sci       Date:  1998-04

Review 4.  The economic costs of asthma: a review and conceptual model.

Authors:  K B Weiss; S D Sullivan
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

Review 5.  The cost of asthma: can it be reduced?

Authors:  C M Mellis; J K Peat; A J Woolcock
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

6.  Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

Authors:  P K Schädlich; J G Brecht
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 7.  Sumatriptan. A pharmacoeconomic review of its use in migraine.

Authors:  A J Coukell; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 8.  Burden of migraine. A review of its socioeconomic impact.

Authors:  G D Solomon; K L Price
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

Review 9.  Economic evaluations of type II diabetes.

Authors:  B Leese
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

10.  Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.

Authors:  P K Schädlich; E Huppertz; J G Brecht
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.